Skip to main content

SABCS 2020 - HER2+

Retreatment with pertuzumab as either third- or fourth-line chemotherapy was both effective and reasonable in patients with HER2-positive locally advanced/metastatic breast cancer and may be considered a standard treatment practice. Read More ›

An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference. Read More ›

Contemporaneous monitoring of HER2 status with circulating tumor cells may help to identify patients who may benefit from modifying the treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

In the HER2-positive metastatic breast cancer setting, trastuzumab-based therapy can support a full recovery. In patients who have achieved a long-term complete response, discontinuation of therapy may be considered appropriate. Read More ›

Based on the premise that BCL-2 may play a key role in HER2-positive breast cancer, a phase 1b/2, randomized, placebo-controlled trial will evaluate venetoclax plus trastuzumab emtansine. Read More ›

De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians. Read More ›

Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen. Read More ›

Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo. Read More ›

This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen. Read More ›

Page 1 of 2